Accuracy and Operational Characteristics of Xpert Human Immunodeficiency Virus Point-of-Care Testing at Birth and Until Week 6 in Human Immunodeficiency Virus-exposed Neonates in Tanzania

Issa Sabi, Hellen Mahiga, Jimson Mgaya, Otto Geisenberger, Sabine Kastner, Willyhelmina Olomi, Elmar Saathoff, Lilian Njovu, Cornelia Lueer, John France, Leonard Maboko, Nyanda Elias Ntinginya, Michael Hoelscher, Arne Kroidl, Issa Sabi, Hellen Mahiga, Jimson Mgaya, Otto Geisenberger, Sabine Kastner, Willyhelmina Olomi, Elmar Saathoff, Lilian Njovu, Cornelia Lueer, John France, Leonard Maboko, Nyanda Elias Ntinginya, Michael Hoelscher, Arne Kroidl

Abstract

Background: Point-of-care (PoC) systems for early infant diagnosis (EID) may improve timely infant human immunodeficiency virus (HIV) management. Experiences within African public health settings are limited.

Methods: We evaluated the accuracy and operational feasibility of the Xpert HIV-1 Qual for PoC-EID testing, using fresh blood and dried blood spots (DBS) samples at obstetric health facilities in Tanzania at birth and at postpartum weeks 1, 2, 3, and 6 in HIV-exposed infants. Test results were confirmed using TaqMan DBS HIV-deoxyribonucleic acid and/or plasma HIV-ribonucleic acid (RNA) testing.

Results: At week 6, 15 (2.5%) out of 614 infants were diagnosed with HIV; 10 (66.7%) of them at birth (median HIV-RNA 4570 copies/mL). At birth, the Xpert-PoC and Xpert-DBS were 100% sensitive (95% confidence intervals: PoC, 69.2-100%; DBS, 66.4-100%) and 100% specific (PoC, 92.1-100%; DBS, 88.4-100%). By week 3, 5 infants with intra/postpartum HIV-infection (median HIV-RNA 1 160 000 copies/mL) were all correctly diagnosed by Xpert. In 2 cases, Xpert-PoC testing correctly identified HIV-infection when DBS tests (Xpert and TaqMan) were negative, suggesting a greater sensitivity. In 2 infants with confirmed HIV at birth, all tests were negative at week 6, possibly because of viral suppression under nevirapine prophylaxis. Problems were reported in 183/2736 (6.7%) of Xpert-PoC tests, mostly related to power cuts (57.9%).

Conclusions: We demonstrated excellent Xpert HIV-1 Qual performance and good operational feasibility for PoC-EID testing at obstetric health facilities. Week 6 sensitivity issues were possibly related to nevirapine prophylaxis, supporting additional birth PoC-EID testing to avoid underdiagnosis.

Clinical trials registration: NCT02545296.

Figures

Figure 1.
Figure 1.
Study flow. Abbreviation: HIV, human immunodeficiency virus.

References

    1. Joint United Nations Programme on HIV/AIDS. UNAIDS Data 2017 Available at: . Accessed 22 January 2018.
    1. Bourne DE, Thompson M, Brody LL, et al. . Emergence of a peak in early infant mortality due to HIV/AIDS in South Africa. AIDS 2009; 23:101–6.
    1. Marston M, Becquet R, Zaba B, et al. . Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. Int J Epidemiol 2011; 40:385–96.
    1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2nd edn 2016. Available at: . Accessed 22 January 2018.
    1. Gill MM, Hoffman HJ, Mokone M, et al. . Assessing very early infant diagnosis turnaround times: findings from a birth testing pilot in Lesotho. AIDS Res Treat 2017; 2017:2572594.
    1. Diallo K, Kim AA, Lecher S, et al. . Early diagnosis of HIV infection in infants - one Caribbean and six Sub-Saharan African countries, 2011-2015. MMWR Morb Mortal Wkly Rep 2016; 65:1285–90.
    1. Tiam A, Gill MM, Hoffman HJ, et al. . Conventional early infant diagnosis in Lesotho from specimen collection to results usage to manage patients: where are the bottlenecks?PLoS One 2017; 12:e0184769.
    1. Thiha S, Shewade HD, Philip S, et al. . Early infant diagnosis of HIV in Myanmar: call for innovative interventions to improve uptake and reduce turnaround time. Glob Health Action 2017; 10:1319616.
    1. Wexler C, Cheng AL, Gautney B, Finocchario-Kessler S, Goggin K, Khamadi S; HITSystem Team Evaluating turnaround times for early infant diagnosis samples in Kenya from 2011-2014: a retrospective analysis of HITSystem program data. PLoS One 2017; 12:e0181005.
    1. Lilian RR, Kalk E, Technau KG, Sherman GG. Birth diagnosis of HIV infection in infants to reduce infant mortality and monitor for elimination of mother-to-child transmission. Pediatr Infect Dis J 2013; 32:1080–5.
    1. Joint United Nations Programme on HIV/AIDS. UNAIDS 2015 progress report on the global plan Available at: . Accessed 22 January 2018.
    1. Chatterjee A, Tripathi S, Gass R, et al. . Implementing services for Early Infant Diagnosis (EID) of HIV: a comparative descriptive analysis of national programs in four countries. BMC Public Health 2011; 11:553.
    1. Persaud D, Palumbo PE, Ziemniak C, et al. . Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS 2012; 26:1483–90.
    1. Ceffa S, Luhanga R, Andreotti M, et al. . Comparison of the Cepheid GeneXpert and Abbott M2000 HIV-1 real time molecular assays for monitoring HIV-1 viral load and detecting HIV-1 infection. J Virol Methods 2016; 229:35–9.
    1. Hsiao NY, Dunning L, Kroon M, Myer L. Laboratory evaluation of the Alere q point-of-care system for early infant HIV diagnosis. PLoS One 2016; 11:e0152672.
    1. Technau KG, Kuhn L, Coovadia A, Murnane PM, Sherman G. Xpert HIV-1 point-of-care test for neonatal diagnosis of HIV in the birth testing programme of a maternity hospital: a field evaluation study. Lancet HIV 2017; 4:e442–8.
    1. Ibrahim M, Moyo S, Mohammed T, et al. . Brief report: high sensitivity and specificity of the Cepheid Xpert HIV-1 qualitative point-of-care test among newborns in Botswana. J Acquir Immune Defic Syndr 2017; 75:e128–31.
    1. Dunning L, Kroon M, Fourie L, Ciaranello A, Myer L. Impact of birth HIV-PCR testing on the uptake of follow-up early infant diagnosis services in Cape Town, South Africa. Pediatr Infect Dis J 2017; 36:1159–64.
    1. Jani IV, Meggi B, Mabunda N, et al. . Accurate early infant HIV diagnosis in primary health clinics using a point-of-care nucleic acid test. J Acquir Immune Defic Syndr 2014; 67:e1–4.
    1. Word Health Organization. WHO prequalification of in vitro diagnostics: Xpert® HIV-1 Qual assay. June2016. Available at: . Accessed 22 January 2018.
    1. Dunning L, Francke JA, Mallampati D, et al. . The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: a cost-effectiveness analysis. PLoS Med 2017; 14:e1002446.
    1. Burgard M, Blanche S, Jasseron C, et al. . Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr 2012; 160:60–6 e1.
    1. Maritz J, Maharaj JN, Cotton MF, Preiser W. Interpretation of indeterminate HIV-1 PCR results are influenced by changing vertical transmission prevention regimens. J Clin Virol 2017; 95:86–9.
    1. Haeri Mazanderani AF, Du Plessis NM, Thomas WN, Venter E, Avenant T. Loss of detectability and indeterminate results: challenges facing HIV infant diagnosis in South Africa’s expanding ART programme. S Afr Med J 2014; 104:574–7.
    1. Department of Health, Republic of South Africa. National consolidated guideline for PMTCT and the management of HIV in children, adolescents and adults April 2015. Available at: . Accessed 22 January 2018.
    1. Persaud D, Gay H, Ziemniak C, et al. . Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828–35.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel